ID.1
Item
1. provision of written informed consent
boolean
C0021430 (UMLS CUI [1])
ID.2
Item
2. a diagnosis of unipolar depression by diagnostic and statistical manual of mental disorders- fourth edition (dsm-iv-tr)
boolean
C0041696 (UMLS CUI [1])
ID.3
Item
3. females and males aged 19-65 years
boolean
C0001779 (UMLS CUI [1])
ID.4
Item
4. female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (hcg) test at enrolment
boolean
C0009862 (UMLS CUI [1,1])
C0032961 (UMLS CUI [1,2])
ID.5
Item
5. able to understand and comply with the requirements of the study
boolean
C1321605 (UMLS CUI [1])
ID.6
Item
6. minimum 21-item ham-d grid score of 15
boolean
C4273889 (UMLS CUI [1])
ID.7
Item
7. prior treatment with therapeutic doses of an ssri-type antidepressant for at least 6 weeks
boolean
C0360105 (UMLS CUI [1])
ID.8
Item
8. unsatisfactory response to treatment, as determined by clinician, for at least 6 weeks.
boolean
C0521982 (UMLS CUI [1])
ID.9
Item
1. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
ID.10
Item
2. any dsm-iv axis i disorder not defined in the inclusion criteria
boolean
C0270287 (UMLS CUI [1])
ID.11
Item
3. english as a second language
boolean
C1546417 (UMLS CUI [1])
ID.12
Item
4. patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
boolean
C0563664 (UMLS CUI [1,1])
C0149660 (UMLS CUI [1,2])
C1271966 (UMLS CUI [1,3])
ID.13
Item
5. known intolerance or lack of response to quetiapine fumarate, as judged by the investigator
boolean
C0724680 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C1320680 (UMLS CUI [1,3])
ID.14
Item
6. use of any of the following cytochrome p450 3a4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir
boolean
C2962753 (UMLS CUI [1])
ID.15
Item
7. use of any of the following cytochrome p450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, st. john's wort, and glucocorticoids
boolean
C3500477 (UMLS CUI [1])
ID.16
Item
8. administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation
boolean
C2585377 (UMLS CUI [1])
ID.17
Item
9. substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by dsm-iv criteria
boolean
C0085762 (UMLS CUI [1,1])
C0013146 (UMLS CUI [1,2])
ID.18
Item
10. opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by dsm-iv criteria within 4 weeks prior to enrolment
boolean
C0029095 (UMLS CUI [1,1])
C0236807 (UMLS CUI [1,2])
C0338700 (UMLS CUI [1,3])
C0009171 (UMLS CUI [1,4])
C0006868 (UMLS CUI [1,5])
C0018526 (UMLS CUI [1,6])
ID.19
Item
11. medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
boolean
C0012634 (UMLS CUI [1,1])
C0025519 (UMLS CUI [1,2])
C0000854 (UMLS CUI [1,3])
C1704711 (UMLS CUI [1,4])
C2699704 (UMLS CUI [1,5])
ID.20
Item
12. unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension) as judged by the investigator
boolean
C0012634 (UMLS CUI [1])
ID.21
Item
13. involvement in the planning and conduct of the study
boolean
C0681871 (UMLS CUI [1])
ID.22
Item
14. previous enrolment or randomisation of treatment in the present study.
boolean
C2347180 (UMLS CUI [1])
ID.23
Item
15. participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements
boolean
C0008976 (UMLS CUI [1,1])
C0586510 (UMLS CUI [1,2])
ID.24
Item
16. previous head injury, associated with loss of consciousness.
boolean
C0018674 (UMLS CUI [1])
ID.25
Item
17. neurological disorder.
boolean
C0027765 (UMLS CUI [1])
ID.26
Item
18. significant physical health problem
boolean
C0012634 (UMLS CUI [1])
ID.27
Item
19. an absolute neutrophil count (anc) of 1.5 x 109 per liter;
boolean
C0948762 (UMLS CUI [1])
ID.28
Item
20. a patient with diabetes mellitus (dm) fulfilling one of the following criteria:
boolean
C0011849 (UMLS CUI [1])
ID.29
Item
unstable dm defined as enrollment glycosylated hemoglobin (hba1c) >8.5%.
boolean
C0019018 (UMLS CUI [1])
ID.30
Item
admitted to hospital for treatment of dm or dm related illness in past 12 weeks.
boolean
C0011849 (UMLS CUI [1,1])
C4060672 (UMLS CUI [1,2])
ID.31
Item
not under physician care for dm
boolean
C0583348 (UMLS CUI [1])
ID.32
Item
physician responsible for patient's dm care has not indicated that patient's dm is controlled.
boolean
C0583348 (UMLS CUI [1,1])
C0421258 (UMLS CUI [1,2])
ID.33
Item
physician responsible for patient's dm care has not approved patient's participation in the study. has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomization. for thiazolidinediones (glitazones) this period should not be less than 8 weeks.
boolean
C0359086 (UMLS CUI [1])
ID.34
Item
taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks note: if a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.
boolean
C0745343 (UMLS CUI [1])